MedTech growth concerns likely to overshadow Q3 results, Leerink says
BUZZ-MedTech growth concerns likely to overshadow Q3 results, Leerink says ** Leerink Partners says it remains cautious about the MedTech sector ahead of Q3 earnings, citing a "somewhat murky" near-term backdrop
** Points to growing competition in certain markets, including cardiac devices and diabetes care, uncertain procedure volumes amid higher costs, weakening consumer sentiment and hospital budget pressure from rising interest rates
** "We suspect that even positive 3Q results in isolation could be overshadowed by lingering concerns regarding the earnings and growth backdrop for 2027 and beyond," brokerage says
** Says company-specific catalysts can help Medtronic MDT.N, Tandem Diabetes Care TNDM.O outperform broader sector headwinds
** Most cautious on PROCEPT BioRobotics PRCT.O and Insulet PODD.O, as slowing adoption trends and rising competition could lead to downward revisions to 2027 expectations, brokerage says
(Reporting by Siddhi Mahatole)
Recent news on Abbott Laboratories
See all newsBrief: Abbott Announces Availability Of Panbio Covid-19/Flu A&B Self-Test In Canada
Perrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement